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potential future therapies. The hereditary neuropathies are in an era of molecular insight and over the past
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has also improved the diagnosis as well as the understanding of CMT. A greater understanding of the molecular
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Inherited peripheral neuropathies, like many other degenerative
disorders, have been challenging to treat. At this point, there is little
speciﬁc therapy for the inherited neuropathies other than genetic
counseling as well as symptomatic treatment and rehabilitation. In
the past, ascorbic acid, progesterone antagonists, and subcutaneous
neurotrophin-3 (NT3) injections have demonstrated improvement in
animal models of CMT 1A, the most common inherited neuropathy,
but have failed to translate any effect in humans. Given the difﬁculty
in treatment, it is important to understand the molecular pathogenesis
of hereditary neuropathies in order to strategize potential futureAD, Autosomal dominant; AR,
city; CMAP, Compound muscle
MSN, Hereditary motor sensory
crosis factor (TNF)-alpha factor;
y sensory neuropathy; Cx32,
hin-3; INF2, Inverted formin 2;
ride-induced tumor necrosis
n-2; SBF2, SET binding factor 2;
atricopeptide repeat domain 2;
ynamin 2; GJB1, Gap junction
e 1; HSPB1, Heat-shock protein
uscular Diseases: Pathology and
1 319 353 7911.therapies. The hereditary neuropathies are in an era ofmolecular insight
and over the past 20 years, more than 78 subtypes of CMT have
been identiﬁed and extensively studied to understand the biological
pathways in greater detail. Next generation molecular sequencing has
also improved the diagnosis as well as the understanding of CMT. A
greater understanding of the molecular pathways will help pave the
way to future therapeutics of CMT.
2. Background
Inherited neuropathies are some of the most common inherited
neurological disorders [1]. Inherited neuropathies not part of another
syndrome are named hereditary motor and sensory neuropathy
(HMSN) or Charcot Marie Tooth disease (CMT). CMT stands for Charcot
Marie Tooth, named after three neurologists who described the condi-
tion in 1886 [2]. CMT is the most common inherited disorder of the
human peripheral nerve with a prevalence of 1 in 2500 [3]. While
CMT is used as a term for hereditary motor and sensory neuropathies,
it may also be viewed as a spectrum ranging from the pure motor neu-
ropathies (HMNs) to the predominantly pure sensory neuropathies
(HSNs); the following reviewwill focus on hereditarymotor and senso-
ry neuropathies.
Over the past 25 years, a dramatic revolution in molecular genetics
of inherited neuropathies has occurred. More than 40 genes causing
CMT have been identiﬁed with many different types of mutations.
These mutations provide clues into the cellular pathways of inherited
neuropathies and knowledge of cellular pathways can help provide
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the majority (over 90%) of all CMT molecular diagnoses: peripheral
myelin protein 22 (PMP22), gap junction β-1 (GJB1), myelin protein
zero (MPZ), and mitofusion 2 (MFN2) [5], new genes have recently
been found to be associated with CMT including PDK3 [6], GNB4 [7],
INF2 [8], and FBLN5 [9,10].Table 1
CMT subtypes, genes, and protein product: function.
Disrupted process Disease Gene
Schwann cell
Myelin assembly CMT1A,
CMT1E,
HNPP
PMP22
CMT1B,
CMT2I/2J,
CMTDID
MPZ
Cytoskeleton CMTDIE INF2
CMT 4F PRX
CMT 4H FGD4
Channel CMT X1 GJB1 or
Cx-32
Transcription,
mRNA processing
CMT 4E,
CMT 1D
EGR2
Endosomal sorting
and cell signaling
CMT1C LITAF
CMT 4B1 MTMR2
CMT4B2 SBF2
CMT4B3 SBF1
CMT 4C SH3TC2
CMT 4D NDRG1
CMT 4J FIG4
CMTDIB,
CMT 2M
DNM2
Mitochondria CMT 4G HK1
Neuron cell body and axon
Proteasome and
protein aggregation
CMT 2F HSPB1
CMT 2L HSPB8
CMT 2P LRSAM1
CMT 2R TRIM2
Cytoskeleton, axonal transport CMT 1F,
CMT 2E
NEFL2
CMT 2O DYNC1H1
Channel CMT 2C TRPV4
Nuclear envelope,
mRNA processing
CMTDIC YARS
CMT 2B1 LMNA
CMT 2B2 MED25
CMT 2D GARS
CMT 2N AARS
CMT 2 MARS
CMT 2 HINT1
CMT X5 PRPS1
CMTRIB KARS
CMT RIC PLEKHG5
Endosomal sorting
and cell signaling
CMTDIF GNB4
CMT 2B RAB7A
CMT 2G TFG
Mitochondria CMT 2A MFN2
CMT 4A,
CMT2K,
CMT RIA
GDAP1
CMT2Q DHTKD1
CMT X4 AIFM1
CMT X6 PDK3Current classiﬁcation of CMT depends on electrophysiological stud-
ies and patterns of inheritance. Subtypes include autosomal dominant
demyelinating (CMT 1), autosomal dominant axonal (CMT 2), autoso-
mal recessive (CMT 4) and X-linked (CMTX). Demyelinating CMT
(CMT 1) is characterized by motor nerve conduction velocity (MNCV)
less than 38 m/s in the forearm [11]. Dominant intermediate CMTProtein product: function
Peripheral myelin protein 22: myelin assembly
Myelin P0 protein: myelin assembly
Inverted formin 2: actin polymerization and ﬁlament severing
Periaxin: membrane–protein interactions stabilizing myelin sheath
Frabin protein: regulates cell signaling involved in myelin production
and involved in actin cytoskeleton
Gap junction beta-1 or connexin-32: gap junction formation +
myelin assembly and transport
Early growth response-2: transcription regulation
Lipopolysaccharide-induced tumor necrosis factor-alpha
factor: regulation of endosome to lysosome trafﬁcking and cell signaling
Myotubularin-related protein-2: modiﬁes chemical messengers,
which are involved in signal transduction
SET binding factor 2: development of Schwann cells
SET binding factor 1: endosomal trafﬁcking [13]
SH3 domain and tetratricopeptide repeat domain 2: targets
to intracellular endosome recycling
N-myc downstream-regulated gene 1: signaling protein
shuttling between cytoplasm and nucleus
FIG4 protein: abnormal transport of intracellular organelles
Dynamin 2: family of large GTPases and part of cell
fusion–ﬁssion apparatus
Hexokinase 1: glucose metabolism
Heat-shock protein beta-1: microtubule regulator
Heat-shock protein beta-8: microtubule regulator
Leucine-rich repeat and sterile alpha motif-containing 1: E3 ubiquitin ligase,
regulates cell adhesion molecules
Tripartate motif-containing protein 2: E3 ubiquitin ligase
Neuroﬁlament light chain: intermediate ﬁlaments in neurons
Dynein, cytoplasmic 1 heavy chain 1: retrograde axonal transport
Transient receptor potential cation channel subfamily V member 4: calcium
homeostasis, cytoskeleton remodeling
Tyrosyl-tRNA synthetase: aminoacyl tRNA synthetase
Lamin A/C: intermediate ﬁlament protein of nuclear envelope
Mediator complex subunit 25: regulated transcription of RNA
polymerase II-dependent genes
Glycyl-tRNA synthetase: aminoacyl tRNA synthetase
Alanyl-tRNA synthetase: aminoacyl tRNA synthetase
Methionyl-tRNA synthetase: aminoacyl tRNA synthetase
Histidine triad nucleotide binding protein 1: modulates transcriptional activity
Phosphoribosyl pyrophosphate synthetase 1: purine and pyrimidine biosynthesis
Lysyl-tRNA synthetase: aminoacyl tRNA synthetase
Pleckstrin homology domain-containing protein, Family G,
member 5: nuclear factor kB-Activator
Guanine nucleotide-binding protein B4: signal transduction
Ras-related protein Rab-7: vesicular transport and membrane trafﬁc
Trk-fused gene: endoplasmic reticulum morphology
Mitofusin-2:mitochondrial fusion
Ganglioside-induced differentiation-associated
protein 1: mitochondria ﬁssion
2-Oxoglutarate dehydrogenase E1 component: degradation of amino acids
Apoptosis-inducing factor mitochondrion associated 1: oxidative
phosphorylation; apoptosis
Pyruvate dehydrogenase kinase, isoenzyme 3: regulates pyruvate
dehydrogenase complex
Fig. 1. Genes causing CMT associated with various neuronal and Schwann cell structures: localizations of genes associated with neuron cell body, axon, and Schwann cell are listed.
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45 m/s on MNCVs [2]. Axonal CMT (CMT 2) is characterized by
MNCVs N 45 m/s as well as a compound muscle action potential
(CMAP) amplitude decrease. CMT can be divided based on the disrupted
process of themutated gene (Table 1). The following review will utilize
the molecular function at the cellular level as the basis of classiﬁcation
and will be divided based on function and protein produced. Each
CMT subtype is named based on molecular ﬁndings in myelinated
axons [12].
This review will also address the molecular processes involved in
different types of CMT (Fig. 1). Genes encode for proteins in the
Schwann cell and neuron (Table 1). These proteins are involved in the
following processes: myelin assembly, cytoskeleton/axonal transport,
protein aggregation, endosomal sorting, mitochondrial functions,
mRNA processing/transcription, and channel abnormalities. When
these proteins are mutated, various cellular processes are disrupted,
thus resulting in CMT.3. Myelin assembly: PMP22, MPZ
A distinguishing feature of axons in the central and peripheral
nervous system is themyelin sheath, which increases electrical impulse
propagation speed [13]. Myelin is a multi-layer spiral structure
ensheathing axons that are larger than 1 μm thick; Schwann cells form
the myelin sheath in the peripheral nervous system and the
oligodendrocytes do the same in the central nervous system. One
Schwann cell myelinates a single axon unlike oligodendrocytes, which
myelinate multiple axons. Myelin allows for an increase in axonal
conduction velocity without an increase in axonal diameter through
the process of salutatory conduction in which nerve impulses jump
between nodes of Ranvier, which are gaps between two myelin
segments. Although myelinating Schwann cells are responsible for ademyelinating neuropathy, neurons that express a mutant protein can
also contribute in a demyelinating neuropathy.
The myelin sheath has two areas, compact and non-compact, which
contain unique proteins (Fig. 2) [14]. The compact region contains
the myelin structural proteins PMP22, P0 (MPZ encodes it), and
myelin basic protein [14]. Most of the myelin is compact, containing
cholesterol, sphingolipids, galactocerebroside, and sulfatide. The
non-compact region is formed in part because of the long distances
between the cell nucleus and Schwann cells; the non-compact myelin
contains gap junctions that provide a radial pathway to the myelin
sheath for the passage of water, Schmidt–Lanterman incisures, ions,
and small molecules. The non-compact myelin can be divided into
the paranode, directly adjacent to the node of Ranvier and the
juxtaparanode region. The paranodal region contains loops of Schwann
cell membrane which contains Schwann cell proteins such as Cx32, the
major gap-junction protein inmyelin. It also containsmyelin associated
glycoprotein (MAG), neurofascin 155, and axonal proteins Caspr and
Contactin. The juxtaparanodal region contains potassium channels and
Caspr2, both expressed by axons.
Schwann cells and axons also interact along the peripheral nerve
internodes, which provide mutual beneﬁts to both cells including
trophic support. Disorders that occur in Schwann cells, like in CMT 1,
result in axonal loss, theﬁnal pathway of all CMT disease. Thus Schwann
cells serve as a source of neuroprotection [15]. Schwann cell and axonal
interactions are disrupted with virtually all demyelinating inherited
neuropathies as there are signiﬁcant changes in axonal physiology.
This mutual relationship is evidenced by secondary axonal degenera-
tion in all forms of demyelinating CMT that are observable clinically as
muscle atrophy and physiologically, by reduced amplitudes on nerve
conduction testing.
Mutations in Schwann cells can cause disease both by interfering or
reducing the normal function of the speciﬁc molecule (loss of function)
or by introducing abnormalities not related to the normal function
Fig. 2. A. Myelinated axon. A schematic depiction of the node, paranode, and juxtaparanode.
B. Laser scanning confocal micrograph of Na+ and K+ channels. A myelinated ﬁber teased
from rat sciatic nerve was labeled with a rabbit antiserum against voltage-gated Na+
channels (rhodamine) and amonoclonal antibody against Kv1.2 (ﬂuorescein). Na+ channels
are restricted to the node (double arrowheads), where Kv1.2 channels are found in the
juxtaparanodal region (arrowheads).
Courtesy of Dr. Steven Scherer, University of Pennsylvania.
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abnormalities often cause more severe disease than heterozygous loss
of function. One example is when the mutation interferes with normal
folding and processing of the protein in the endoplasmic reticulum.
This example has been investigated in particular with certain PMP22
and MPZ point mutations [14,16,17]. When the misfolded PMP22 or
MPZ accumulate in the Schwann cell ER they activate a process
known as the unfolded protein response (UPR) which can globally
downregulatemyelination.Manipulating theUPR is a current therapeu-
tic strategy in these disorders [18].
3.1. Peripheral myelin protein 22 (PMP22) mutations: CMT 1A, HNPP, CMT
1E (17p12)
Peripheral myelin protein 22 (PMP22) causes CMT 1A, the most
common form of CMT, when one of its alleles is duplicated and heredi-
tary neuropathywith liability to pressure palsy (HNPP)when an allele is
deleted. Thus CMT 1A and HNPP are caused by dosage abnormalities of
PMP22. Missense mutations in PMP22 are said to cause CMT 1E to
distinguish them from CMT 1A. The PMP22 gene encodes a 22-kDa
protein that makes up 2–5% of peripheral nervous system myelin
proteins. It is produced by Schwann cells and expressed in the compact
myelin in all myelinated ﬁbers of the peripheral nervous system [19].
Its functional role is still debated. It was ﬁrst identiﬁed as a growth
arrest gene (Gas 3) in ﬁbroblasts. However whether it plays a role
in the cell cycle of Schwann cells is uncertain. CMT 1A is caused by aduplication (overexpression) of PMP22, a 1.4 mega base (Mb) duplica-
tion on chromosome 17p11.2–p12; it is one of the most common
inherited neuropathies and is usually caused by the heterozygous inher-
itance of two homologous DNA sequences of PMP22. HNPP is caused by
a deletion (under expression) of PMP22, resulting in loss-of-function
alleles. Pathologically, biopsies of those with HNPP will show nerves
forming tomacula (folding of myelin sheath, demyelination, and
remyelinating). Tomacula are unstable structures that are prone to
degeneration, thus resulting in disease manifestations [20]. Point
mutations causing CMT 1E are relatively rare, causing around 1% of
cases of CMT.
Peripheral myelin protein 22 (PMP22) is a molecule that can form
aggresomes when mutated, thus forming PMP22 aggregates. Some
experimental studies have shown that autophagy enhancement can
reduce accumulated PMP22 protein aggregates [21]. PMP22 may also
interact with P0, so that an abnormal PMP22/P0 ratio could make the
myelin sheath unstable. Mutant PMP22 could have additional effects,
which include blocking wild-type PMP22 transportation to the cell
membrane by a dominant negative effect [22].
3.2. Myelin protein zero (MPZ) mutation: CMT 1B, CMT 2I/J,
CMT DID (1q23.3)
The major and most abundant myelin protein produced by
myelinating Schwann cells is myelin protein zero or P0 [23]. The gene
formyelin protein zero,MPZ (aka P0) has beenmapped to chromosome
1q22. Virtually all MPZmutations that alter the coding sequence cause a
dominantly inherited neuropathy with varying phenotypes [1].
Myelin protein zero accounts for more than 25% of the myelin
protein in peripheral nerve sheaths. MPZ links adjacent lamellae and
stabilizes myelin assembly [24,25]. MPZ makes up most of compact
myelin. It contains a high positively charged intracellular domain with
an extracellular single immunoglobulin, which is important for myelin
compaction [1]. As in PMP22, the dose of P0 in myelin is important
with reduced MPZ causing myelin instability and overexpression
causing severe dysmyelination. MPZ is a transmembrane protein
that is made in the endoplasmic reticulum where it undergoes
N-glycosylation and forms an intramolecular disulﬁde bond.
If MPZ is misfolded, MPZ proteins can collect in the endoplasmic
reticulum causing an unfolded protein response leading to Schwann
cell apoptosis and subsequent demyelination [14]. Toxicity of misfolded
protein or reduced amounts of P0 could be the etiology behind the
phenotypic manifestations of many patients with MPZ mutations [14].
More than 200 different disease-causing mutations in MPZ have
been identiﬁed (http://www.molgen.ua.ac.be/CMTMutations/default.
cfm). Many patients with CMT 1B present in two phenotypic groups:
one with extremely slow nerve conduction velocities and onset of
symptoms during the period of motor development; and a second
with normal or near normal nerve conduction velocities and the onset
of symptoms as adults [26]. Why particular mutations cause early or
late onset neuropathy is not understood [1].
4. Myelin assembly: future therapeutic strategies
4.1. Curcumin: reduction of neurotoxic aggregates/misfolded proteins
Khajavi et al. (2005) found that frameshift mutations of MPZ associ-
ated with severe disease result in intercellular accumulations of mutant
proteins in tissue culture especially in the endoplasmic reticulum [27].
In mouse models of early-onset CMT 1B, speciﬁc mutations in the MPZ
gene (S63del and R98C) were seen; mutant S63del and R98C MPZ
accumulate in the endoplasmic reticulum of Schwann cells, triggering
an unfolded protein response and dedifferentiation of these cells, with
consequent demyelination. Curcumin, a chemical compound derived
from the curry spice turmeric relieves the endoplasmic reticulum stress
as it has been shown to mitigate the phenotype in mice models.
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inherited peripheral neuropathies.
4.2. Geldanamycin: prevention of PMP22 aggregates
Inhibition of heat shock protein 90 by geldanamycin treatment can
also prevent PMP22 protein aggregates [21]. Geldenamycin enhanced
cytosolic chaperone levels and improved myelination, along with the
trafﬁcking of PMP22 in mice [28]. Preclinical therapeutic studies have
not been performed yet.
4.3. Nutrient deprivation or rapamycin: autophagy to remove aggresomes
In Schwann cells of Trembler-Jmice, the protein degrading pathways
of the lysosome and proteasome are full and abnormal cytosolic
aggregates containing mutant misfolded PMP22 and ubiquitin are
formed. Induction of autophagy (which removes aggresomes) via nutri-
ent deprivation or rapamycin resulted in aggresome degradation in
Schwann cells of PMP22 mutant and overproducing mice [21,29].
4.4. Onapristone: progesterone receptor antagonist
Progesterone encourages myelination in the peripheral nervous
system as well as stimulating PMP22 and MPZ expression [30].
Experiments have shown that daily administration of progesterone to
CMT 1A rats increased levels of PMP22 andMPZmRNA in sciatic nerves,
resulting in a more severe neuropathy. Administration of a progester-
one receptor antagonist (onapristone), reduced overexpression of
PMP22 mRNA and thus improved the CMT phenotype (speciﬁcally
improving the axonal loss seen during disease progression) [31,32]. At
this point, onapristone has been toxic, so currently a safer progesterone
antagonist is being developed [31].
4.5. Ascorbic acid: normalization of gene dosage
Ascorbic acid is critical in myelination; it promotes the formation of
collagen and laminin containing extracellular matrix and seems to
promote myelinating Schwann cells. A mouse model of CMT 1A was
treatedwith high doses of ascorbic acid andmyelinationwas improved;
there was also a reduction in PMP22 mRNA levels to those below what
was necessary to induce the disease [33]. Although ascorbic acid
reduces the severity of neuropathy in transgenic mice overexpressing
PMP22 compared to untreated mice, it has no signiﬁcant effect
in humans with CMT 1A testing with different doses of vitamin C
(1–4 g/d) for over 2 years [34]. Both ascorbic acid and progesterone
antagonists are nonspeciﬁc therapies and do not target expression of a
singlemyelin gene, whichmay be appropriate for CMT 1A but unknown
for other types of CMT [14].
4.6. Small molecule screens and normalization of gene dosage
The Charcot Marie Tooth Association has spearheaded an ongoing
effort to use high throughput screen (HTS) technology to identify
potential existing compounds that have the potential to lower the
dosage of PMP22 in patients with CMT 1A. A study in 2012 describes
compounds from a collection of 3000 approved drugs which were
tested at multiple titration points to achieve a pharmacological end
point in an HTS format. In conjunction with an independent counter-
screen for cytotoxicity, an orthogonal screen platform designed was
effective to select and prioritize active compounds, among which
three drugs (fenretinide, olvanil, and bortezomib) were shown to
reduce endogenous Pmp22 mRNA and protein [35]. These studies are
currently in progress although no current compounds have yet been
investigated in human trials.4.7. siRNA and antisense oligonucleotides: normalization of gene dosage
Small double stranded RNAs (dsRNA) of about 21 nucleotides are
used in plants and animals to degrade mRNA and genetically
engineered small inhibitory RNAs (siRNAs) can be engineered to reduce
the expression of targetmRNAs such as PMP22 in patientswith CMT1A;
other molecules such as ribozymes and antisense oligonucleotides can
downregulate levels of mRNAs as well.
5. Cytoskeleton: INF2, PRX, FGD4, FBLN5 (Schwann cell) and NEFL2,
DYNC1H1 (neuron)
The cytoskeleton, nucleus, and mitochondria are several biological
elements that deﬁne eukaryotic cells. The cytoskeleton is composed of
three distinct structures: microtubules, intermediate ﬁlaments, and
microﬁlaments [36].
Microtubules form a hollow tube of about 13 protoﬁlaments, which
form an outer diameter of 25 nm; they serve as tracks for organelle
trafﬁc. Microtubules of neurons are unique as axonal and dendritic
microtubules have uniform polarity with plus ends that are distal to
the cell body; the microtubules are not continuous back to the
cell body and they do not have a microtubule organizing center [37].
Neuronal microtubules are more diverse with a variety of composition
according to location (i.e. axon vs. dendrite). Axonal microtubules,
for instance, are so stable that they resist treatments that could
depolymerizemicrotubules of other cells [38]. Microtubule cytoskeletal
proteins of the nervous system include alpha and beta-tubulin.Microtu-
bules also have microtubules associated proteins, which interact with
microtubules; microtubule associated proteins include those that have
a high molecular weight, such as tau proteins, and those that have an
intermediatemolecular weight, such as kinesin, and dynein. In neurons,
microtubules assist in the transport of membrane-bound organelles,
extend neurites during development, provide scaffolding for neuritis,
and maintain intracellular compartments.
Intermediate ﬁlaments can be divided into ﬁve subtypes: keratin
ﬁlaments in epithelial cells, vimentin ﬁlaments in mesenchymal cells,
desmin inmuscle cells, glial ﬁlaments in astrocytes, and neuroﬁlaments
in neurons. Neuroﬁlaments form 8 to 10 nm rope-like ﬁlaments
that support neuronal and glial cells. Neuroﬁlaments unlike other inter-
mediate ﬁlaments have side arms that project outward; instead of being
densely packed like other intermediate ﬁlaments, neuroﬁlaments are
widely spread out. Mutations of neuroﬁlaments may result in abnormal
neuroﬁlaments and thus reduce the axon diameter and caliber [39].
Actin microﬁlaments are critical in neuronal grown and secretion;
they are formed into 4–6 nm diameter ﬁbrils like an intertwined string
of pearls [40].
5.1. Inverted formin 2 (INF2): CMTDIE (14q32.33)
INF2 protein is a member of the formin family that binds to
growing ends of actin ﬁlaments, and protects them from being
cross-linked into bundles [41,42]. INF2 interacts with actin and
essentially accelerates both polymerization and depolymerization
of actin ﬁlaments [41]. INF2 is expressed in peripheral nerve
Schwann cells, some axons, and podocytes of the kidney [8]. When
INF2 is mutated, Schwann cell actin is disrupted, leading to abnormal
myelin formation and CMT.
Individuals with this mutation not only had CMT, but they also
had sensorineural hearing loss as well as focal segmental glomerulo-
sclerosis [8].
5.2. Periaxin (PRX): CMT 4F (19q13.2)
Mutations in periaxin cause the autosomal recessive CMT 4F [43].
Periaxin is a cytoskeletal component and membrane associated protein
of Schwann cells located in non-compact myelin [43]. Periaxin is
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and the bands of Cajal (which are important for proper elongation
during development) [44]. Its location changes during myelination
from near the axon to near the basal lamina in mature myelin sheaths.
Periaxin interacts with dystroglycan through dystrophin related
protein-2, linking laminin-2 in the basal lamina to the actin cytoskele-
ton, making a complex, which if disrupted will result in demyelinating
neuropathies [1]. Periaxin-deﬁcient mice develop focal myelin
outfoldings (tomacula), infoldings, and progressive demyelination.
They will not display Cajal bands and will show a decreased intermodal
length [44]. Periaxin is involved in membrane–protein interactions that
provide myelin stabilization. It also forms tight junctions between the
myelin loop and axon. In 2010, Marchesi et al. discovered that all
patients with PRX mutations and a neuropathy have truncating muta-
tions in homozygous or compound heterozygous states, suggesting a
loss of protein function as a disease [45]. Animal models of periaxin
mutations show that periaxin deﬁcient mice will myelinate their
peripheral axons normally, but then develop a severe demyelinating
neuropathy with allodynia and hyperalgesia [46].
5.3. Frabin protein (FGD4): CMT 4H (12p11.21)
FGD4 protein is a cytoplasmic guanine nucleotide exchange factor
for cell division cycle 42 and binds along sides of actin ﬁbers [47].
It alters Schwann cell shape and results in a severe demyelinating
neuropathy. Mouse frabin induced the formation of ﬁlopodia in ﬁbro-
blasts [48].
5.4. Neuroﬁlament light chain (NEFL): CMT 1F/2E (8p21.2)
NEFL is one of the three members of the neuroﬁlament family and is
seen only in neurons [49]. Neuroﬁlaments are important and prominent
structures of the axonal cytoskeleton [49]. Mutations in NEFL cause
abnormalities in the neuroﬁlaments, which subsequently lead to a
disruption of neuroﬁlament networks and aggregation and result in
CMT 4H [50]. Neuroﬁlaments have three subunits: light, medium, and
heavy, which become neuronal intermediate ﬁlaments that form the
cytoskeletons of large axons. Brownless et al. in 2002 demonstrated
that abnormal neuroﬁlament disrupted neuroﬁlament assembly and
axonal transport as well as disturbing the localization of mitochondria
in neurons [51]. Neuroﬁlaments are also pathologic in diseases such as
motor neuron disease, Alzheimer's disease, Parkinson's disease,
dementia with Lewy body, and diabetic neuropathy [51].
5.5. Dynein, cytoplasmic 1 heavy chain 1 (DYNC1H1):
CMT 20.LED-SMA (14q32.31)
Mutations in the heavy-chain of the dynein motor protein (encoded
by DNC1H1) result in CMT 20 [52]. Dynein is a motor protein crucial
for neuronal axonal retrograde transport. MicaudalD homolog 2
(Drosophila) encodes an adaptor protein that interacts with DYNC1H1
and also plays a role in facilitating retrograde axonal transport. Recently
dominant mutations in BICD2 have been shown to cause a similar
phenotype to those caused by DYNC1H1 [53].
6. Cytoskeleton: future therapeutic strategies
6.1. Celastrol: a chaperone inducer
Celastrol is an inducer of chaperone proteins, and induces HSPA1
(stress inducible heat shock protein 7) expression in motor neurons; it
prevents the formation of neuroﬁlament inclusions and mitochondrial
shortening induced by expression of NEFL in motor neurons [54]. It
had a protective effect against the toxicity of NEFL in large sized sensory
neurons, but not motor neurons [54].6.2. HDAC-6 inhibitors: targeting transport defects
Histone deacetylase-6 inhibitors have been shown to correct axonal
transport defects in a mouse model of CMT 2F, improving the axonal
loss and clinical phenotype of mice. This is a result of an increased
acetylated tubulin in peripheral nerve of mutant HSPB1 expressing
mice [55]. HDAC6 helps regulate axonal transport and thus could be a
target to treat axonal neuropathies [56].7. Proteasome and protein aggregation
7.1. Proteasome and protein aggregation: HSPB1/HSPB8, LRSAM1, TRIM2
Ubiquitin is crucial in protein degradation in eukaryotic cells [57].
An increase in protein aggregates because of decreased degradation
results in the neuropathology of many neurodegenerative disorders
such as Parkinson's disease, dementia with Lewy body, prion diseases,
and hereditary neuropathies. The neuron is sensitive to protein
aggregates as they are sophisticated post-mitotic cells that need to
remain plastic and renew internal components properly; they are thus
dependent on efﬁcient protein degradation [57].7.2. Heat shock protein beta 1/8 (HSPB1/HSPB8): CMT 2F/2L
(7q11.23/12q24.3)
Mutations in HSPB1 (also called HSP 27), and HSPB8 (heat shock
proteins) cause CMT 2F and CMT 2L respectively. HSPB1 and HSPB8
are members of the heat shock protein superfamily and are protective
stress proteins [58]. Heat shock proteins maintain neuronal integrity
and function. They regulate and maintain the cytoskeleton as well as
microtubules. They interact with intermediate ﬁlament proteins. Heat
shock proteins appear also to play a role in muscle contraction. When
mutated, they are not transported and form protein aggregates [58].
These aggregates are thought to interfere with axon function and
disrupt neuroﬁlament assembly, affecting axon diameter and nerve
impulse transmission.7.3. Leucine-rich repeat and sterile alpha motif-containing 1
(LRSAM1): CMT 2P (9q33.3)
Leucine-rich repeat and sterile alpha motif-containing 1 is an E3
ubiquitin ligase that regulates cell adhesion molecules and plays a role
in receptor endocytosis and viral budding.7.4. Tripartate motif-containing protein 2 (TRIM 2): CMT 2R (4q31)
Mutations in the TRIM gene results in an inability to degrade
unwanted proteins via ubiquitin, which moves unwanted protein
into proteasomes. TRIM2 is an E3 ubiquitin ligase that ubiquitinates
neuroﬁlament light chain.8. Proteasome: future therapeutic strategies
8.1. Arimoclomol: coinducer of heat shock protein
A promoter polymorphism has been found in HSPB1 that impairs
the stress response of this protein and may be a risk factor for motor
neuron disease [59]. Arimoclomol, a coinducer of heat shock proteins,
delays disease progression in SOD1 mutant ALS mice, implying
that these proteins are important to motor neuron survival [60]. This
suggests that molecules that upregulate heat shock proteins can be
beneﬁcial for motor neuron disease and other neurodegenerative
diseases such as distal HMN [61]; this could include CMT also.
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9.1. Endocytic cycling/membrane trafﬁcking: CMT 1C, CMT 4B1, CMT 4B2,
CMT 4B3, CMT 4C, CMT 4J (Schwann cell) CMTDIF, CMT 2B, CMT 2G
(neuron)
Defects in membrane trafﬁcking and degradation are common
themes of many neurodegenerative disorders (Alzheimer's disease,
Parkinson's disease, trinucleotide repeat expansion diseases, peripheral
neuropathies, and lysosomal storage disorders); these defects result in
undegraded proteins due to abnormal endosomal, lysosomal, or
autophagic activity [62].
9.2. Lipopolysaccharide-induced tumor-necrosis
factor: LITAF/SIMPLE: CMT 1C (16p13)
SIMPLE mutations result in dominantly inherited CMT 1C. The
SIMPLE gene is expressedwidely and encodes a 161-amino acid protein
that plays a role in protein degradation [63]. Although the exact function
is unknown, it is essentially involved in facilitating membrane proteins
to the lysosome for degradation [14,64]. SIMPLE mutations cause a
predominantly demyelinating neuropathy event though it is expressed
inmany cells types. Because the phenotype appears very similar to CMT
1A it has been suggested that impaired degradation of Schwann cell
proteins such as PMP22 may be involved [14].
9.3. Myotubularin-related protein-2 (MTMR2): CMT 4B1 (11q22)
Mutations in MTMR2 cause CMT 4B1. The pathological characteris-
tics of CMT 4B1 demonstrate damage in myelinating Schwann cells
which demonstrate a characteristic myelin outfolding. MTMR2 is a
member of the myotubularin related dual speciﬁc phosphatases,
whose substrates are phosphorylated inositol phospholipids [65]. The
MTMR mutations result in reduced or absent 3′ phosphatase activity.
Phosphoinositides control intracellular membrane trafﬁcking, and thus
mutations may result in altered endocytic or exocytotic process or
abnormal membrane transport pathways. Membrane trafﬁcking is
critical for myelin membrane biogenesis and homeostasis [66].
MTMR2 interacts with neuroﬁlament light chain, which has an impor-
tant role in axon development [67]. The phenotype is identical to that
caused by mutations in MTMR13/SBF2, described below. This is
presumably because MTMR2 and MTMR13 interact with each other in
carrying out their phosphatase activity.
9.4. Set binding factor 2 (SBF2/MTMR13): CMT 4B2 (22q13)
Similar to MTMR2, SPF2/MTMR13 belongs to a family of proteins
that regulate vesicular trafﬁcking in Schwann cells and their loss leads
to uncontrolled folding of myelin [68]. A mouse model of abnormal
SPF2 developed a demyelinating peripheral neuropathy, myelin
outfoldings and infoldings seen on nerve biopsies, and progressive
demyelination similar to CMT 4B2 [68]. Furthermore, MTMR2 levels
were also decreased in 50% of SPF2 deﬁcient sciatic nerves, suggesting
a relationship between the two proteins [68]. SPF2 and MTMR2 play
an important role in the sorting and modulating of cellular signaling.
9.5. Set binding factor 1 (SBF1/MTMR5): CMT 4B3 (11p15)
Even though SBF1/MTMR5 molecular pathways have not been fully
understood, it is similar in structure toMTMR2and SBF2. SBG1has func-
tions similar to other myotubularin-related proteins. The current
hypothesis is that SBF1 may play a role in motor cells. SBF1 interacts
withMTMR2 via a coiled-coil domain and SBF1 increases the enzymatic
activity of MTMR2 commanding its subcellular localization [13].9.6. SH3 domain and tetratricopeptide repeat domain 2
(SH3TC2): CMT 4C (5q32)
CMT 4C is the most common recessive CMT in North America and
Northern Europe. SH3TC2 has been found to participate in the endocytic
pathway of cell trafﬁcking and is anchored to the plasma membrane
[69]. SH3TC2 is located to structures of the endocytic pathway, the
clathrin coated vesicles including the trans-Golgi network, early
endosomes, late endosomes, and other domains of the plasma
membrane [69]. SH3TC2 is thought to be involved maintaining myelin
formation via trafﬁcking membrane components from the trans-Golgi
network to the endocytic compartments [69]. Early and pronounced
scoliosis is a characteristic feature of patients with CMT 4C [70].
9.7. N-myc downstream-regulated gene 1 (NDRG1): CMT 4D (8q24.3)
Mutation in NDRG1 results in a “Lom type” of CMT as Lom is the
Bulgarian City where it was ﬁrst described [68]. There is Schwann cell
dysfunction and early axonal loss suggesting impairment of axon–glial
interaction. NDRG1 plays a role in growth arrest and cell differentiation
as a signaling protein shuttling between the cytoplasm and nucleus
[71]. Studies have suggested that failed endosomal transport processes
from abnormal Schwann cell trafﬁcking failed to meet the demands of
nerve growth, which was the likely pathogenetic mechanism in
NDRG1 deﬁciency [68].
9.8. FIG4: CMT 4J (6q21)
FIG4 is a lipid phosphatase involved in vesicle trafﬁcking; it removes
the 5-phosphate from phosphatidylinositol-3,5-bisphosphate located
on the cytoplasmic surface of vesicles of the endosome/lysosome
pathway [68]. MTMR2 and FIG4 have shown to interact together in
neurons and Schwann cells to control phospholipid metabolism [68].
The CMT 4J phenotype has been unusual in that some patients have
had a slowly developing demyelinating neuropathy during childhood
that has rapidly accelerated and resulted in death as adults. It may be
that there are independent pathogenic processes occurring in Schwann
cells and neurons in this unique disease [72,73].
9.9. Trk-fused gene (TFG): CMT 2G (3q12.2)
TFGwas identiﬁed as part of the neurotrophic tyrosine kinase recep-
tor type 1 in human papillary carcinoma [74]. TFG inhibition in cell lines
slows protein secretion from the endoplasmic reticulum and alters
endoplasmic reticulum morphology, disrupting organization of the
peripheral tubules of the endoplasmic reticulum, and collapsing the
endoplasmic reticulum onto the microtubule cytoskeleton. TFG forms
a matrix between the endoplasmic reticulum sites and the ER-Golgi
area and serves as a sorting hub for secretory material. It also provides
long-term axonal maintenance [74].
9.10. Ras-related protein Rab-7 (RAB7A): CMT 2B (3q13–q22(61))
CMT 2B is caused by mutations in RAB7 gene. Rab7 encodes
Ras-associated GTP-binding protein 7, which regulates intracellular
membrane vesicle led transport. If mutated, it disrupts the vesicular
transport to late endosomes and lysosomes in the endocytic pathway.
It causes a primarily sensory neuropathy that clinically resembles
hereditary sensory neuropathy type 1 (HSN1). Mutations in Rab7 has
made GTPase activity abnormal and slowed nucleotide dissociation
[49]. Rab7 controls endocytic sorting by axonal retrograde transport.
Rab proteins are involved in trafﬁcking of motor proteins and vesicular
trafﬁcking as well as transportation of proteins to the cytoskeleton [75].
Rab7 is involved in lysosomal transport. Rab 7 mediates microtubule
based transport of early melanosomes suggesting a link between Rab7
and cytoskeleton [49]. Rab7 and Rab5 control endocytic sorting by
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(RILP) controls lysosomal transport by recruiting the dynein–dynactin
motor system [76].9.11. Dynamin 2 (DNMT2): CMTDIB/CMT 2M (19p13.2)
Mutations in DNM2, which encodes Dynamin-2 result in dominant
intermediate CMT 2D and CMT 2M. Dynamin-2 helps change the cell
membrane and cytoskeleton to form vesicles.Mutations in DNM2 result
in altered microtubule dynamics, which is important in correcting
axonal transport [4]. DNM2 seems to help assist the separation of
newly formed endosomes from the cell membrane [14,77].9.12. G protein beta-4 subunit (GNB4): CMTDIF (3q26.33)
Heterotrimeric G proteins are important for signal transduction from
an activated receptor to effectors. GNB4 is widely expressed in all cell
types and GB4 is thought to modulate important effector systems like
N-type calcium channels, GIRK potassium channels, and phospholipase
isoforms [78].10. Mitochondria
10.1. Mitochondrial role in inherited neuropathies: MFN2, GDAP1, PDK3,
AIFM1, DHTKD1, HK1
Neurons contain hundreds of mitochondria that help with a
neuron's large energy demands. Mitochondria form cable-like struc-
tures along neuronal projections and have a dynamic structure and
function. Mitochondria are transported up and down axons by antero-
grade and retrograde transport systems. They are strategically
positioned in sites where ATP supply and calcium handling are required
in neurons [79]. Neurons need energy for the transport of organelles
and cargo along microtubules or actin; energy is also needed
for maintaining ion gradients, the membrane potential with ATP-
dependent calcium, ion channels, neurotransmitter-vesicle loading at
presynaptic terminals, calcium mediated neurotransmitter release,
and sodium–potassium pumps. Neurons depend on mitochondrial
function to maintain membrane excitability and to process neurotrans-
mission and plasticity [80].10.2. Mitofusin-2 (MFN2): CMT 2A (1p36.22)
Mutations in MFN2 account for 20% of CMT 2 [2]. MFN2 is located in
the outer membrane of mitochondria. MFN2 depletion causes CMT by
impairing oxidative phosphorylation and cell bioenergetics [2].
Mitofusin 2 is necessary for mitochondria to fuse, as mitochondria
need to be fused into chains before being transported by kinesin KIF1B
[14,81]. MFN2 is a GTPase that is located in the outer mitochondrial
membrane, and helps mediate mitochondrial fusion. MFN2 mediates
the tethering of the endoplasmic reticulum and mitochondrial
membranes [82]. MFN2 mutations not only cause mitochondrial fusion
disruption but also severe axonal transport defects [83,84]. Disrupted
axonal transport may cause CMT 2A, which ultimately results in
length-dependent axonal degeneration as mitochondria need to be
transported to distal axons and dendrites. Repairing the axonal
transport is one therapeutic approach to treating many disorders
including CMT 2A. Another approach is to try and upregulate another
mitofusin, MFN1, in neurons. MFN1 is also located on the outer
mitochondrial membrane, promotes fusion to other mitochondria, and
has been shown to complement (overcome) MFN2 induced abnormal-
ities in culture [85] and in mice [86].10.3. Ganglioside induced differentiation-associated protein-1
(GDAP1): CMT 4A, CMT 2K, CMT RIA (8q21.11)
GDAP1 mutations cause CMT 4A. GDAP1 protein is expressed by
neurons and Schwann cells, and the encoded protein is predicted to
have two transmembrane domains and a glutathione S-transferase
domain, suggesting a role in antioxidant pathways [87]. GDAP1 is a
nuclear encoded gene expressed by both neurons and Schwann cells,
which has a protein product localized to the mitochondrial outer
membrane; it affects mitochondrial ﬁssion (rather than fusion, which
is mediated by MFN2). GDAP1 activity is dependent on ﬁssion factors
Drp1 and Fis1 and promotes ﬁssion without increasing the risk of
apoptosis. Mutant GDAP1 can cause mitochondrial fragmentation
when mutated [88]. Mutant GDAP, like MFN2, might be connected to
the microtubular network in peripheral axons, which could lead to
transport defects of the mitochondria [49]. GDAP1 is expressed by
both neurons and Schwann cells, and it has been hypothesized that
they can cause either a demyelinating or axonal early onset severe
sensorimotor neuropathy [2]. Most GDAP1 mutations cause recessively
inherited neuropathy but a few speciﬁc mutations can cause dominant-
ly inherited CMT. The inheritance pattern could affect the underlying
mitochondrial cellular mechanism that is impaired [88].
10.4. Pyruvate dehydrogenase kinase, isoenzyme 3
(PDK3): CMT X6 (Xp22.11)
PDK3 is an isozyme for pyruvate dehydrogenase kinase, which is
located in the mitochondrial matrix and regulates the pyruvate
dehydrogenase complex. It converts pyruvate to acetyl-coA, which is
oxidized in the mitochondria to produce energy in the citric acid cycle.
A mutation in PDK3 results in the PDK3 to be “open”, leading to
increased activity that locks the pyruvate dehydrogenase complex in
an inactive state building up to impaired ATP production and lactate
accumulation [6].
10.5. Apoptosis-inducing factor mitochondrion-associated 1
(AIFM1): CMT X4 (Xq26.1)
The AIFM1 gene encodes for an apoptosis-induced factor that results
in oxidative phosphorylation in normal healthy cells. AIFM1 is released
frommitochondria andmoves to the nucleus, where nuclear features of
apoptosis (chromatin condensation and large-scale DNA degradation)
are mediated [89]. Mutations result in increased apoptotic cells.
10.6. 2-Oxoglutarate dehydrogenase E1 component
(DHTKD1): CMT 2Q (10p14)
DHTKD1 has an important role in mitochondrial energy produc-
tion and nerve development. DHTKD1 encodes a mitochondrial
2-oxoglutarate-dehydrogenase-complex-like protein involved in
amino acid degradation. Mutations in DHTKD1 lead to abnormal
energy production (as can be seen by decreased ATP and decreased
total NAD and NADH levels) [90].
10.7. Hexokinase 1 (Hk1): CMT 4G (10q22.1)
Hexokinase 1 catalyzes the ﬁrst step in glucose metabolism via ATP
for phosphorylating glucose to glucose-6-phosphate. It is hypothesized
that mutated Hk1 alters myelin protein synthesis regulation, axonal
transport, and axon–Schwann cell interactions [91].
11. Therapeutic strategies for abnormal mitochondrial function
Focusing on mitochondrial function could be an area of potential
therapeutic research (given the involvement of CMT 2A with MFN2,
GDAP's role with CMT 4A, and HSP27's role in CMT 2F).
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Studies have shown that both Mfn1 and Mfn2 are involved in
mitochondrial fusion. Neural tissues have low Mfn1 expression and
are vulnerable when Mfn2 is mutated and neither Mfn1 nor Mfn2
exist. Studies have attempted to increase Mfn1 expression in the
peripheral nervous system, which would beneﬁt CMT 2A patients.
Wild-type Mfn2 can form heterooligomeric complexes to complement
mutantMfn2; thus,methods thatwould increaseMfn1 can be beneﬁcial
in those with CMT 2A [85].
12. mRNA processing
12.1. mRNA processing and transcription factors: GARS/YARS/MARS/AARS/
KARS, MED 25, HINT1, PRPS1, PLEKHG5
RNA processing occurs before the formation of proteins during
translation. Mutations in genes involving RNA processing appear to
cause primarily CMT rather than a disorder of all cell processes.
12.2. Glycyl/tyrosyl/methionyl/alanyl/lysyl-tRNA synthetases: (GARS/YARS/
MARS/AARS/KARS): CMT 2D (7p14)/CMTDIC (1p35)/CMT 2 (12q13.3)/
CMT2N (16q22)/CMTRIB (16q23)
Aminoacyl-tRNA synthetases are vital in protein synthesis as they
attach the proper amino acid to its appropriate tRNA in the cytoplasm
andmitochondria. These enzymes are necessary for each cell to undergo
translation and for the proper protein to be formed; CMT is caused
by mutations in a number of these enzymes, which thus link protein-
synthesizing complexes with neurodegeneration [92].
GARS is a glycyl-tRNA transferase that is responsible for placing
glycine on the appropriate tRNA.
Missense mutations in GARS cause CMT 2D [93].
Similarly, YARS [92], MARS [32], AARS, and KARS are responsible for
placing tyrosyl, methionyl, alanyl, and lysyl on the appropriate tRNA
respectively. Mutations in YARS cause CMTDIC; mutations in MARS
cause CMT 2. Interestingly, a Drosophila model of CMTDI has been
created with a YARS mutation; this induced a progressive deﬁcit of
motor function with axonal degeneration [94].
AARS is involved in aminoacylation and editing function; mutations
could lead to qualitative errors in neurodegeneration causing CMT 2N
[95].
KARS is associated with recessive intermediate CMT (CMT RIB), and
in patients with this mutation, not only do they have CMT, but they also
have developmental delay, self-abusive behavior, dysmorphic features,
and vestibular Schwannoma [96].
12.3. Mediator complex subunit 25 (MED 25): CMT 2B2 (19q13.33)
MED 25 is a transcriptional co-activator involved in transcriptional
regulation; it is a subunit of the human activator-recruited cofactor
(ARC), a family of large transcriptional coactivators related to the
yeastmediator.Mutation ofMED25 causes a decreased binding speciﬁc-
ity for SH3 domain proteins, which are found in proteins of signaling
pathways regulating the cytoskeleton, Ras protein, and many others
[97]. MED25 gene is expressed with the PMP22 gene dosage and
expression in transgenic mice and rats, which suggests the role of the
protein in CMT 2B2 aswell as a role in peripheral neuropathy pathogen-
esis [97].
12.4. Histidine triad nucleotide-binding protein 1 (HINT 1): CMT 2 (5q23.3)
The HINT1 gene encodes a purine phosphoamidase, and has been
implicated as a tumor suppressor protein that is involved in apoptotic
pathways [98]. In vitro, HINT1 hydrolyzes lysyl-AMP that is generated
by lysyl-tRNA synthetase [98]. Maintenance and function of HINT1 isimportant for peripheral nerve physiology but the exact mechanism is
still in question; there is some suggestion that HINT 1 is linked with
transcriptional regulation and RNA metabolism [97]. HINT1 also could
modulate the B-catenin transcriptional activity, and HINT1 mutations
could also lead to toxic metabolites [98]. Patients with HINT mutations
appear to originate largely from eastern European populations [68].
12.5. Phosphoribosyl pyrophosphate synthetase 1
(PRPS1): CMT X5 (Xq22.3)
PRPS1 is a member of the PRPS gene family; it is expressed in all
human cells including the cochlea. It mediated the critical biochemical
step for purinemetabolism and nucleotide biosynthesis [99]. Mutations
result in CMTX5,which includes a severe axonal neuropathy, peripheral
neuropathy, hearing loss, and optic neuropathy [99].
12.6. Pleckstrin homology domain-containing protein, family G, member 5
(PLEKHG5): CMT RIC (1p36.31)
PLEKHG5mutations cause RICMTC as it was found that if mutated it
had a defect in activating the NF-κB signaling pathway, which is
involved in DNA transcription. NF-κB responds to multiple stresses
(cytokines, free radicals, bacterial or viral antigens) and plays a key
role in regulating the immune response to viral infection. Incorrect
regulation of NF-κB can lead to peripheral neuropathy as well as cancer,
inﬂammation, autoimmune disease, and improper immune develop-
ment. PLEKHG5 is expressed in the peripheral nervous system, and
contains a motif known as the minimal unit for the nucleotide
exchange-promoting function of guanine nucleotide exchange factors
[100]. It is involved in neuronal cell differentiation [100]. Neurotoxicity
could be due to the loss of function in the NF-κB transduction pathway
and aggregate formation of mutant PLEKHG5 [100].
12.7. Early growth response 2 (EGR2): CMT 4E, CMT 1D (10q21.3)
EGR2 (historically termed KROX-20) is a zinc ﬁnger transcription
factor, which is a regulator of Schwann cell differentiation and myelin
gene expression. EGR2 transcription factor is critical for peripheral
nerve myelination. Expression of EGR2 in Schwann cells increases
the expression of myelin related genes such as MPZ, PMP22, GJB1,
and PRX [101]. EGR2 mutants dominant-negatively inhibit wild-type
EGR2 mediated expression of essential myelin genes to levels low
enough that result in abnormal myelination and result in CMT 4E and
CMT 1D [101].
13. Channel
13.1. Neuronal channel: TRPV4A, GJB1
Transmembrane ion channels allow ions to move into or out of cells.
Neuronal channels allow for neurotransmission by changing the polar-
ization of the neuronal membrane. Neuronal ion channel activation
can occur in a voltage- or ligand-gated manner. Each channel is usually
selective for one ion type (sodium, calcium, potassium, chloride).
13.2. Gap junction beta-1 protein or connexin 32
(GJB1 or Cx32): CMT 1X (Xq13)
Cx32 is encoded by GJB1; mutations of GJB1 can result in loss of
function mutations and dysfunctional gap junctions that disrupt
communication between Schwann cells and neurons, all leading to
CMT 1X [102]. CMT 1X is the second most frequent form of CMT,
affecting about 15% of all patients with CMT [103]. Cx32 is located in
non-compact myelin and forms functional channels, allowing for rapid
transport of ions between two cells via radial migration of the
myelin layers [2,104]. Six connexins form a hemichannel and two
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myelinating Schwann cells and helps form gap junctions between the
myelin sheath; the gap junctions are aligned radially, thus making a
shorter pathway than a circumferential route [105]. A disruption of
the radial pathway of the gap junctions could result in demyelination.
Mutant Cx32 in the endoplasmic reticulum or Golgi could affect
intracellular trafﬁcking and trigger cellular clearance responses [106].
Recent studies have found that intracellular trafﬁcking, abnormal
synthesis, and loss of gap junction function are the main alterations of
the majority of CMT 1X mutations [107].
There are more than 400 different CMT 1X GJB1 mutations, which
affect different aspects of the Cx32. The clinical manifestations,
however, are more homogenous with late childhood onset and more
axonal loss than CMT 1A. The clinical manifestations in women vary
depending on the number of myelinating Schwann cells that make the
X chromosome with the mutant allele inactive [108].
13.3. Transient receptor potential cation channel of the vanilloid-type
member 4 (TRPV4A): CMT 2C (12q 23–24)
TRPV4 is responsible for encoding a calcium permeable nonselective
channel that plays a role in regulating systemic osmotic pressure.
Mutant TRPV4 could cause increased calcium inﬂux and calcium
overload, which could be deleterious to axonal transport [109,110].
14. Therapeutic approaches (other)
14.1. Trophic factors and CMT
Neurotrophins are growth factors; they have the ability to promote
development of both neurons and glia; many of the trophic factors are
expressed in Schwann cells and levels are altered in nerve injury [14].
The trophic factors include NGF (nerve growth factor), BDNF
(brain derived neurotrophic factor), neurotrophin-3 (NT3) and
neurotrophin-4/5. Each is secreted as a homodimer, and then cleaved
by a protease. Neurotrophins bind to a protein Trk receptor that
activates downstream signaling pathways in the target cell. Some
studies have shown that trophic factors such as NT3 may be beneﬁcial
in the future; NT3 has been reported to promote nerve regeneration
after injury and the survival of Schwann cells [111]. Therapeutic
application of NT3 in immune incompetentmice of sural nerve biopsies
from patients with CMT 1A promoted axonal regeneration [112].
In eight patients with CMT 1A, NT3 treatment was tolerated three
times aweek over sixmonths. Patients showed an increase inmyelinat-
ed ﬁber density, a reduction in the neurological impairment score and
improved sensory modalities when compared with the controls [112].
Future larger studies need to be performed to conﬁrm results. Overall
results, however, have been disappointing as attempts to halt diseases
such as familial ALS have been unsuccessful. This may be due to
methods of delivery and short half-lives of trophic factors (only several
minutes) [14].
14.2. Schwann cell and axonal interaction treatment strategies
Strategies to treat the Schwann cell and axonal interaction
abnormality include providing trophic factor support, the use of
potassium channel blockers (3,4 diaminopyridine) to prevent
potassium ions from leaking out of the axon during depolarization,
sodium channel blockers (which would prevent the neuron from
overworking by inhibiting the sodium channels to depolarize the axon
in the generation of the axon potential), and manipulating signaling
pathways between the Schwann cell and axon. The latter could
be done using the adaxonal internode and the paranodal region of
the myelinating Schwann cell. Furthermore, Nrg1, which belongs to
the epidermal growth factor family regulates myelin thickness, and
could potentially be used to manipulate myelin thickness in the future[14]. Treatment strategies are being targeted to develop a method to
regulate PMP22 mRNA levels [14].14.3. Stem cells
Stem cells could potentially develop into Schwann cells or neurons,
but it would be difﬁcult to have stem cells differentiate into neurons,
generate into axons and then travel down a limb. Stem cells, however,
could be used as a trophic support for inherited neuropathies (like
NT3) [14]. In certain studies of motor neuron disease and elsewhere,
stem cells have the potential to provide trophic support of mesenchy-
mal stromal cells. Stems cells can also result in transdifferentiation; a
study has shown that mouse ﬁbroblasts and hepatocytes can
transdifferentiate into neurons [113]. Studies taking advantage of this
approach are currently ongoing.14.4. Gene replacement
Gene replacement could be done with mutant genes causing neu-
ropathy by a simple loss of function of the normal gene. Autosomal re-
cessive forms of CMT such as CMT 4, for example, could be cured with
simple gene replacement as there is a simple loss of function of the nor-
mal gene. A major challenge for this type of approach is being able to
speciﬁcally target adequate numbers of Schwann cells or neurons to
make this approach feasible. This approach could also be considered
for dominant CMT caused by clear loss of function mutations such as
in HNPP. Other targets for gene replacement are nonsense mutations
that can result in a premature termination of the mutant protein in
which mRNAs are degraded [14,114].14.5. Cellular reprogramming and high-throughput drug screening
Cellular reprogramming can be used to search for compounds to
treat CMT; cellular reprogramming generates speciﬁc cell types (such
as stem cells, neurons, or glia) by genetically modifying somatic cells
such as ﬁbroblasts or lymphocytes [115]. Using this technique, research
can generate supplies of patient speciﬁc cell lines used for mechanistic
studies and drug development [116]. These cell lines will be useful
when combined with high-throughput screening of drug libraries con-
taining thousands of these compounds. The process of identifying com-
pounds that are capable of correcting certain disease related cell
phenotypes is created in a way for a faster target selection of com-
pounds to be tested in phase 1 animal studies.15. Conclusion
Although neuromuscular disorders such as CMT have been challeng-
ing to treat, the abundance of knowledge regarding genes, proteins
associated with genetic mutations, and speciﬁc cellular functions of
these proteins will further the advancement of therapeutic strategies
and drug trials in the future.Acknowledgements
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